Propensity Score Matched Analysis of External Beam Radiotherapy With or Without Focal Boost to Intraprostatic Lesions in Prostate Cancer
Open Access
- 11 March 2025
- journal article
- Published by Wiley in The Prostate
- Vol. 85 (8) , 805-813
Abstract
Background: This study evaluated the impact of radiotherapy (RT) with or without a simultaneous integrated boost (SIB) to intraprostatic lesions on survival, recurrence, and toxicity in localized prostate cancer (PCa). Key prognostic and predictive factors were also analyzed.Materials and Methods: A retrospective analysis included 712 intermediate‐ and high‐risk PCa patients treated with external beam RT at 78 Gy, with or without SIB (up to 86 Gy), between 2010 and 2018. Propensity score matching (PSM) was used to ensure comparability. Outcomes assessed included biochemical disease‐free survival (bDFS), prostate cancer‐specific survival (PCSS), local recurrence (LR), distant metastasis (DM), and treatment‐related toxicities.Results: After PSM, 417 patients were analyzed (208 with SIB, 209 without). Over a median follow‐up of 8.6 years, the SIB group showed higher 8‐year bDFS (93.8% vs. 83.5%; p = 0.006) and lower rates of DM (6.1% vs. 13.0%; p = 0.003) and LR (1.8% vs. 6.9%; p = 0.03). PCSS was similar between groups (95.7% vs. 92.3%; p = 0.38). Advanced T stage and absence of SIB were predictors of worse bDFS, DM, and LR, while higher Gleason score were associated with poorer PCSS and DM in multivariable analysis. There were no significant differences in 8‐year Grade ≥ 2 GU (10.1% vs. 10.5%; p = 0.98) or GI (7.8% vs. 6.5%; p = 0.64) toxicities between the SIB and non‐SIB groups.Conclusions: SIB with external beam RT significantly improves bDFS and reduces LR and DM in intermediate‐ and high‐risk PCa, with no increase in significant toxicities. These findings emphasize the value of dose escalation in achieving better local control and long‐term outcomes while maintaining patient safety.Keywords
This publication has 30 references indexed in Scilit:
- Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic reviewWorld Journal of Urology, 2024
- Treatment outcomes of simultaneous integrated boost to intraprostatic lesions with external beam radiotherapy in localized prostate cancer patientsThe Prostate, 2023
- Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate CancerEuropean Urology, 2022
- Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)European Urology, 2022
- Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate CancerJAMA Oncology, 2018
- Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Is it essential to use fiducial markers during cone-beam CT-based radiotherapy for prostate cancer patients?Japanese Journal of Radiology, 2016
- Does Local Recurrence of Prostate Cancer After Radiation Therapy Occur at the Site of Primary Tumor? Results of a Longitudinal MRI and MRSI StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Effect of Increasing Radiation Doses on Local and Distant Failures in Patients With Localized Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006